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Hideki Muramatsu,1 Seiji Kojima,1 Ayami Yoshimi,2 Yoshiko Atsuta,2 Koji Kato,3
Yoshihisa Nagatoshi,4 Masami Inoue,5 Kazutoshi Koike,6 Takakazu Kawase,7 Masaki Ito,8
Hidemitsu Kurosawa,9 Akihiko Tanizawa,10 Chikako Tono,11 Kazuko Hamamoto,12
Noriko Hotta,13 AkihiroWatanabe,14 Yasuo Morishima,15 Keisei Kawa,5 Hiroyuki Shimada16Because of a small number of patients, only a few studies have addressed the outcome of bone marrow
transplantation (BMT) in children with Philadelphia chromosome–positive (Ph1) chronic myelogenous leuke-
mia (CML), who receive graft from a volunteer-unrelated donor (VUD), especially after practical application
of imatinib mesylate. The outcomes of BMT from a VUD in 125 children with Ph1 CML were retrospectively
reviewed. Patients were identified through the Japan Marrow Donor Program as having undergone BMT be-
tween 1993and2005andwere aged1-19 years at the timeof transplant (median age, 14 years). The probabilities
of 5-year overall survival (OS) and leukemia-free survival (LFS) were 59.3% and 55.5%, respectively. Multivariate
analysis identified the following unfavorable survival factors: infused total nucleated cell dose\314 106 /kg
(relative risk [RR]5 2.43; 95% confidence interval [CI]5 1.33-4.44; P5.004), advanced phase (RR5 2.43;
95% CI5 1.37-4.31; P5.004), and no major cytogenetic response (MCyR) at the time of BMT (RR5 6.55;
95% CI5 1.98-21.6; P5.002). Of the 17 patients treated with imatinib, 15 (88%) achieved MCyR at the time
of BMT, and this group had an excellent 5-year OS of 81.9%. Disease phase, infused total nucleated cell dose,
and cytogenetic response were independent risk factors for survival of unrelated BMT. These findings provide
important information for assessing the indications for and improving outcome in unrelated BMT for the
treatment of pediatric CML.
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Table 1. Patient, Donor, and Transplant Characteristics
CP1
(n5 88)
Advanced
Phase
(n5 37)
Total
(n5 125)
Year of transplantation
1993-1998 45 22 67
1999-2005 43 15 58
Stage of CML at BMT
CP1 88 0 88
CP2 0 12 12
CP3 0 1 1
Advance phase 0 11 11
Blast crisis 0 13 13
Cytogenetic response at BMT
With MCyR 29 4 33
Without MCyR 39 25 64
Unknown 20 8 28
Pretransplantation therapy with IFN-a
No 22 8 30
Yes 66 29 95
Pretransplantation therapy with imatinib
No 72 36 108
Yes 16 1 17
Recipient sex, M/F 56/32 25/12 81/44
Donor–recipient sex
Female donor to male
recipient
20 10 30
Other 68 27 95
Median age at BMT, years
(range)
13 (1-19) 17 (2 -19) 14 (1-19)
Median time from
diagnosis to transplantation,
months (range)
14 (2-111) 19 (5-103) 14 (2-111)
Patient CMV antibody
Negative 25 14 39
Positive 54 21 75
Unknown 9 2 11
ABO mismatch
Match 41 15 56
Major mismatch 29 11 40
Minor mismatch 17 9 26
Unknown 1 2 3
Recipient–donor HLA DNA typing
Match (10/10) 33 8 41
1 alleles mismatch 9 5 14
2 alleles mismatch 19 9 28
3 alleles mismatch 8 3 11
4 alleles mismatch 2 2 4
6 alleles mismatch 0 1 1
Unknown 17 9 26
Conditioning regimen
TBI regimen 66 30 96
Non-TBI regimen 22 7 29
232 Biol Blood Marrow Transplant 16:231-238, 2010H. Muramatsu et al.chronic phase with a matched related donor is 60%-
75% [2-4]; however, this approach is limited by the
availability of HLA-matched family donors. The major-
ity of children who lack an HLA-matched donor receive
a transplant from an alternative donor, such as a volun-
teer-unrelated donor (VUD). EFS is less favorable in
this setting, ranging from 30% to 55% [3-5].
Since the introduction of the novel tyrosine kinase
inhibitor imatinib mesylate, the treatment for Ph1
CML has been completely revised [6]. Imatinib can
induce complete hematologic and cytogenetic remission
in the majority of patients, and follow-up data onpatients
treated only with imatinib indicate that complete cytoge-
netic and major molecular responses are durable, while
drug toxicity is low [7]. The number of transplantations
for Ph1 CML has declined rapidly [8]. But, despite
significant cytogenetic and molecular responses, there
is no evidence that imatinib is curative, and imatinib’s
long-term side effects remain to be determined. Some
patients have successfully stopped imatinib without
recurrence, but some who were polymerase chain reac-
tion (PCR)-negative for a period stopped and then expe-
rienced recurrence [9,10]. Stopping imatinib may be
possible, but effective strategies have yet to be developed.
This is particularly important for pediatric pa-
tients, in whom the goal is cure of the disease rather
than palliation, and for whom long-term survival is
particularly anticipated. The presence of molecular
disease and the emergence of resistant clones in pa-
tients treated with imatinib suggest the need for cau-
tion with regard to abandoning curative therapy by
SCT. The need for information on the current status
of SCT for Ph1 CML and up-to-date results when
considering the treatment of children with Ph1
CML, even in the imatinib era, is evident; however,
few studies have specifically analyzed outcomes of
SCT in children with Ph1 CML [2-5]. The aim of
the present study was to analyze data from 125 chil-
dren with Ph1 CML who underwent bone marrow
transplantation (BMT) from a VUD and identify
factors influencing outcome.GVHD prophylaxis
CsA + MTX 59 22 81
Tacrolimus + MTX 28 15 43
MTX alone 1 0 1
Administration of ATG
No 76 34 110
Yes 12 3 15
Median infused total
nucleated cell dose,
 106 /kg (range)
315
(27-880)
298.5
(29-750)
314
(27-880)
ATG indicates antithymocyte globulin; BMT, bone marrow transplanta-
tion; CML, chronic myelogenous leukemia; CP, chronic phase; CMV,
cytomegalovirus; CsA, cyclosporine; IFN, interferon; GVHD, graft-
versus-host disease; MCyR, major cytogenetic response; MTX, meth-
otrexate; TBI, total body irradiation.PATIENTS AND METHODS
Patients
A retrospective analysis was conducted on behalf of
the Japan Marrow Donor Program (JMDP) and the
Japanese Pediatric Leukemia/Lymphoma Study
Group (JPLSG) CML Committee. Data were col-
lected from 125 children (age at transplantation\20
years) whose donors were identified through the
JMDP and who underwent allogeneic BMT from
a VUD for Ph1 CML between 1993 and 2005. Table
1 summarizes the patient, donor, and transplant char-
acteristics. Patient characteristics in the first chronic
phase (CP1) and in the advanced phase are describedseparately. All patients or their guardians gave written
informed consent for transplantation and submission
of data to the JMDP for further research. This study
Biol Blood Marrow Transplant 16:231-238, 2010 233UR-BMT for Children with CMLwas approved by the Data Management Committee of
the JMDP and by the Ethical Committee of Nagoya
University Graduate School of Medicine.
The 125 children in the study included 81 boys
(65%) and 44 girls (35%). The median age at the
time of BMT was 14 years (range, 1-19 years). Disease
phase at the time of transplantation was defined
according to International Bone Marrow Transplant
Registry (IBMTR) criteria [11]. Eighty-eight patients
(70%) underwent transplantation in CP1. Of the 37
children who underwent transplantation in an ad-
vanced phase of CML, 12 were in CP2, 1 was in
CP3, 11 were in the accelerated phase (AP), and 13
were in blast crisis (BC). Cytogenetic response data
at the time of BMT were available for 97 patients
(78%), of whom 68 were in CP1 and 29 were in an
advanced phase. Major cytogenetic response (MCyR;
# 35% Ph1 cells) was achieved in 33 patients (29
patients in CP1 and 4 patients in CP2). Ninety-five
recipients (76%) were given interferon (IFN)-a, and
17 (14%) were given imatinib before transplantation.
The patients treated with imatinib proceeded to
BMT regardless of their response, according to each
institutes’ therapeutic strategy. The median interval
from diagnosis to transplantation was 14 months
(range, 2-111 months). Fifty-seven patients (46%)
underwent transplantation within 12 months, and 68
(54%) did so after 12 months. Imatinib began to be
used in Japan in 1999, and its use was approved by
the Japanese Health and Welfare Ministry in 2002.
In our cohort, 17 patients (16 in CP1, 1 in AP) received
imatinib before transplantation.
Transplantation Procedures and Recipient–
Donor HLA Matching
All 125 recipients received a BM graft from a VUD
identified through the JMDP. Various preconditioning
regimens were used by individual centers. Of the 125
recipients, 96 (77%) received a preparative regimen
with total body irradiation (TBI). Fifteen recipients
(12%) received antithymocyte globulin (ATG). Cyclo-
sporine A (CsA)–based GVHD prophylaxis was used in
81 patients (65%); tacrolimus-based prophylaxis, in 43
(34%). One patient received only methotrexate (MTX)
as GVHD prophylaxis. HLA-matching data based on
high-resolution DNA typing for HLA-A, -B, -C,
-DRB1, and -DQB1 antigens were available in 99
patients (79%). Of these 99 patients, 41 (41%) were
fully matched at 10/10 alleles, 14 (14%) were mis-
matched at 1 HLA allele, 28 (28%) were mismatched
at 2 HLA alleles, and 16 (16%) were mismatched at
more than 3 HLA alleles.
Definitions, Data Collection, and Statistical
Analysis
The outcomes were analyzed on the basis of
engraftment, grade II-IV acute and chronic GVHD(aGVHD, cGVHD), treatment-related mortality
(TRM), relapse, overall survival (OS), and leukemia-
free survival (LFS). The date of engraftment was
defined as the first of 3 consecutive days with a neutro-
phil count exceeding 0.5 109 /L. aGVHD and
cGVHD were classified according to published crite-
ria [12]. Only patients surviving for .100 days after
transplantation were considered eligible for evaluation
of cGVHD. Relapse of CML was defined by hemato-
logic or cytogenetic evidence of disease. (Data on
molecular evidence of relapse were not available.)
Transplantation data were collected using standard-
ized forms provided by the JMDP. After transplanta-
tion, patient baseline information and follow-up
reports were submitted at 100 days, 6 months, 1 year,
and annually thereafter.
Comparisons between groups were performed
using Fisher’s exact test for categorical variables and
the Mann-Whitney U test for continuous variables.
Survival and time to events were calculated from the
date of transplantation. OS and LFS were estimated
by the Kaplan-Meier method and compared using
the log-rank test. Cumulative incidence curves were
created for TRM. The Cox proportional hazard model
was used to obtain the estimates and the 95% confi-
dence interval (CI) of the relative risk (RR) for predic-
tive factors and to evaluate predictive factors for TRM,
LFS, and OS in a multivariate analysis. The following
variables were evaluated: patient age at the time of
BMT ($ 15/\ 15 years), patient sex, sex mismatch,
year of transplantation (1993-1998/1999-2005), pe-
riod from diagnosis to transplantation ($ 12 months/
\ 12 months), infused total nucleated cell dose ($
314 106/kg/\ 314 106/kg), TBI-containing regi-
men (yes/no), use of ATG (yes/no), GVHD prophy-
laxis (CsA 1 MTX 6 steroids/FK6MTX), full
HLA matching (yes/no), disease phase at the time of
BMT (CP1/advanced phase), MCyR at the time of
BMT (yes/no), ABO mismatch (match/mismatch), re-
cipient cytomegalovirus (CMV) antibody (negative/
positive), history of interferon therapy (yes/no), and
history of imatinib therapy (yes/no). Variables with
more than 2 categories were dichotomized for the final
multivariate model. The cutoff points of the variables
were chosen to make optimal use of the information,
with the proviso that smaller groups contained at least
20% of the patients. The cutoff points of continuous
variables were chosen from the 25th, 50th, and 75th
percentiles; consequently, the median of continuous
variables was dichotomized as follows: age ($15/
\ 15 years), year of transplantation (1993-1998/
1999-2005), and infused total nucleated cell dose ($
314 106/kg/\ 314 106/kg). SPSS version 15.0
(SPSS Inc, Chicago, IL) was used for all statistical
calculations except estimation of the cumulative
incidence, which was performed using Stata version
10.0 (StataCorp, College Station, TX).
Table 2. Patient Clinical Outcomes
CP1 (n5 88)
Advanced Phase
(n5 37) Total (n5 125) P Value
Engraftment .336
Yes/No 85 / 3 34 / 3 119 / 6
Acute GVHD .186
None 21 11 32
Grade I 34 9 43
Grade II 18 5 23
Grade III 11 7 18
Grade IV 4 5 9
Chronic GVHD .393
None 49 25 74
Limited 15 6 21
Extensive 24 6 30
5-year TRM (95% CI) 28.3% (23.4-33.2) 56.5% (48.0-65.0) 36.5% (32.5-40.5) .002
5-year relapse rate (95% CI) 11.8% (8.1-15.5) 29.0% (18.7-39.3) 15.4% (11.7-19.1) .098
5-year LFS (95% CI) 65.2% (60.0-70.4) 32.4% (24.7-40.1) 55.5% (51.0-60.0) .001
5-year OS (95% CI) 70.7% (65.7-75.7) 32.4% (24.7-40.1) 59.3% (54.8-63.8) <.001
GVHD indicates graft-versus-host disease; LFS, leukemia-free survival; OS, overall survival; TRM, treatment-related mortality.
Figure 1. OS and LFS in children with Ph1 CML. In Kaplan-Meier
curves graph, solid line shows the probabilities of OS (5-year
OS5 59.3%; 95% CI5 54.8%-63.8%) and the dotted line shows that
of LFS (5-year LFS5 55.5%; 95% CI5 51.0%-60.0%).
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Engraftment
A total of 119 recipients (95%) were successfully
engrafted. Neutrophil engraftment occurred at a me-
dian of 18 days after BMT (range, 11-37 days). Six pa-
tients (5%) experienced primary graft failure (Table 2),
all of whom died.
aGVHD and cGVHD
Grade II-IV aGVHD occurred in 50 patients
(40.7%; 95% CI5 36.3%-45.1%), and grade III-IV
aGVHD occurred in 27 patients (22.6%; 95%
CI5 16.1%-31.2%). Fifty-one patients (50.1%; 95%
CI5 45.0%-55.2%) developed cGVHD (extensive
type, n5 30; limited type, n5 21).
Relapse
Seventeen patients (11 recipients in CP1 and 6 in
an advanced phase) experienced a relapse. The 5-year
cumulative incidence of relapse was 19.7% (95%
CI5 15.1%-24.3%). The median time for occurrence
of relapse for the entire study cohort was 7 months
(range, 1-97 months).
Survival
LFS
The 5-year LFS rate was 55.5% (95% CI5 51.0%-
60.0%) for the entire cohort (Figure1). The LFS rate
was significantly higher in children undergoing BMT
in CP1 (65.2%; 95% CI5 60.0%-70.4%) than those
undergoing BMT in an advanced phase (32.4%; 95%
CI5 28.7%-36.1%; P5 .001) (Table 2).
On univariate analysis, the following factors were
significantly associated with LFS: age at the time of
BMT (P5 .047), infused total nucleated cell dose(P5 .002), disease phase (P5 .002), and cytogenetic
response at the time of BMT (P5 .001). Multivariate
analysis also identified infused total nucleated cell
dose (RR5 2.320; 95% CI5 1.326-4.061; P5 .003),
disease phase (RR5 2.051; 95% CI5 1.187-3.545;
P5 .010), and cytogenetic response at the time of
BMT (RR5 2.890; 95% CI5 1.264-610); P5 .012)
as independent risk factors for LFS.
OS
The 5-year OS rate was 59.3% (95% CI5 54.8%-
63.8%) for the entire cohort (Figure 1). The OS rate
was significantly higher in the children undergoing
BMT in CP1 (70.7%; 95% CI5 65.7%-75.7%) than
in those undergoing BMT in an advanced phase
(32.4%; 95% CI5 24.7%-40.1%; P\ .001) (Table 2).
On univariate analysis, the following risk factors
were significantly associated with OS: age at the time
of BMT (P5 .037), interval between diagnosis and
Figure 2. A and B, Relationship among infused total nucleated cell dose, OS (A), and TRM (B) in children with Ph1 CML. In the entire cohort, OS was
significantly higher for children who received a higher infused total nucleated cell dose than those who received a lower dose ($ 314 106/kg
vs\314 106/kg; P5.001). TRM was significantly higher for children who received a lower cell dose than for those who received a higher cell
dose ($ 314 106/kg vs\314 106/kg; P5.003). Solid lines show the probabilities of OS and TRM for children who received a higher infused total
nucleated cell dose and the dotted lines show the probabilities for those who received a lower infused total nucleated cell dose. C and D, OS (C) and
TRM (D) of Ph1 CML children in CP1 with or without an MCyR. OS was significantly higher for children who achieved MCyR at the time of BMT
(n5 29) than for those who did not (n5 39) (OS; P\.001) (C). TRM was also significantly higher for children who did not achieve MCyR (P5.005) (D).
The solid lines showthe probabilities of OS and TRM forchildren with MCyR at the time of BMT, and the dotted lines showthe probabilities for those without.
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(P5 .002), disease status (P \.001), and cytogenetic
response at the time of BMT (P5 .002). A history of
imatinib therapy before BMT marginally affected OS
(P5 .099). Multivariate analysis identified infused total
nucleated cell dose (RR5 2.426; 95% CI5 1.326-
4.441; P5 .001) (Figure 2A), disease status (RR5
2.427; 95% CI5 1.368-4.305; P5 .002), and cytoge-
netic response at the time of BMT (RR5 6.547; 95%
CI5 1.982-21.629; P5 .002) (Figure 2C) as indepen-
dent risk factors for OS (Table 3).
Causes of Death
Fifty-two patients (42%) died after BMT from
a VUD (Table 4). The day-100 mortality rate was
15.2 % (95% CI5 12.0%-18.4%). The main cause of
death was transplantation-related complications, from
which 46 patients (37%) died between day 8 and 10
years (median, 4 months) after transplantation. These
included 18 transplantation-related deaths occurring
before day 100 after transplantation. Death was associ-ated with treatment-resistant GVHD in 14 patients (9
with aGVHD and 5 with cGVHD). Infection was the
cause of death in 12 patients. Six patients died from re-
current CML between 3 and 28 months (median, 13
months) after transplantation.
Univariate analysis revealed that infused cell dose
(P5 .013), disease phase (P5 .006), and cytogenetic re-
sponse at the time of BMT (P5 .001) were significant
risk factors for TRM. The interval between diagnosis
to BMT (P5 .083) and HLA mismatch (P5 .087)
were marginally associated with TRM. In the multivar-
iate model, infused cell dose (RR5 2.347; 95%
CI5 1.195-4.610; P5 .013) (Figure 2B) and cytoge-
netic response at the time of BMT (RR5 9.055; 95%
CI5 2.151-38.127; P5 .003) (Figure 2D) were inde-
pendent risk factors for TRM (Table 3).
Effects of HLA Compatibility
The influence of HLA compatibility between
recipient and donor on aGVHD, TRM, and OS was
assessed by univariate analysis. aGVHD (grade II-IV)
Table 3. Risk Factors for TRM and OS on Multivariate
Analysis
Covariates RR (95% CI) P value
TRM
Infused cell dose
$ 314 106/kg (1)
< 314 106/kg 2.347 (1.195-4.610) .013
Cytogenetic response at BMT
With MCyR (1)
Without MCyR 9.055 (2.151-38.127) .003
OS
Infused total nucleated cell dose
$ 314 106/kg (1)
< 314 106/kg 2.426 (1.326-4.441) .004
Disease phase at BMT
CP1 (1)
Advanced phase 2.427 (1.368-4.305) .002
Cytogenetic response at BMT
With MCyR (1)
Without MCyR 6.547 (1.982-21.629) .002
BMT indicates bone marrow transplantation; MCyR, major cytogenetic
response; OS, overall survival; TRM, treatment-related mortality.
236 Biol Blood Marrow Transplant 16:231-238, 2010H. Muramatsu et al.was less frequent in patients with fully matched donors
than in those with mismatched donors (RR5 2.044;
95% CI5 1.055-3.961; P 5 .034). TRM (RR5
1.902; 95% CI5 0.894-4.045; P 5 .095) and OS
(RR5 1.572; 95% CI5 0.817-3.027;P5 .176) tended
to be worse in mismatched transplantation, but the dif-
ference was not statistically significant. In the analysis
of each single allele mismatch, only the HLA-A allele
mismatch significantly affected OS (RR5 2.837; 95%
CI5 1.347-5.977; P 5 .006). HLA-C mismatch
marginally affected OS (RR5 1.639; 95% CI5
0.945-2.843; P 5 .078), whereas HLA-B, -DRB1, and
-DQB1 mismatch were not significant. On multivari-
ate analysis, HLA compatibility was not identified as
an independent risk factor for acute GVHD, TRM,
or OS.Table 4. Causes of Death
CP1
(n5 88)
Advanced
Phase
(n5 37)
Total
(n5 125)
TRM 26 20 46
Infections
Bacterial 4 1 5
Fungal 1 0 1
Viral 3 1 4
Pneumocystis jirovecii 1 0 1
Unknown 0 1 1
Rejection 0 1 1
Acute GVHD 5 4 9
Chronic GVHD 4 1 5
Idiopathic interstitial pneumonitis 6 4 10
Cardiac failure 0 1 1
Respiratory failure 0 1 1
Renal failure 1 1 2
Hemorrhage 0 2 2
Secondary malignancy 1 0 1
Unknown 0 2 2
Relapse 1 5 6
CP indicates chronic phase; GVHD, graft-versus-host disease; TRM,
treatment-related mortality.Effect of Cytogenetic Response at
Transplantation
Cytogenetic response data were available in 68 of
88 patients (77%) who underwent transplantation in
CP1. Sixteen patients received imatinib, 35 received
IFN-a, and 3 received neither imatinib nor IFN-a.
MCyR at the time of BMT was achieved in 15 of the
16 patients (94%) treated with imatinib and in 14 of
the 35 patients (40%) treated with IFN-a.
Patients with MCyR at the time of BMT (n5 29)
had significantly better OS and LFS than those with-
out MCyR (n5 39): 5-year OS5 91.4%, 95%
CI5 85.4%-97.4% versus 53.4% and 45.3%-61.5%
(P5 .001); 5-year LFS5 81.0 %, 95% CI5 73.2%-
88.8% versus 50.9% and 42.8%-59.0% (P5 .02)
(Figure 2C). Although no significant difference in re-
lapse rate was seen between the 2 patient groups
(P5 .91), TRM was significantly lower in those who
achieved MCyR at the time of BMT (n5 29) than in
those who did not (n5 39): 5-year TRM5 9.6 %,
95% CI5 3.0%-16.2% vs 41.0% and 32.7%-49.3%
(P5 .005) (Figure 2D).
Effect of Pre-BMT Imatinib Therapy
In this cohort, 17 patients received imatinib before
transplantation, and 15 of them (88.2%) achieved
MCyR in CP1 before transplantation. This percentage
was significantly higher than that in the patients who
did not receive imatinib (88.2% vs 22.2%; P\ .01).
A history of imatinib therapy had a positive effect on
survival (5-year OS5 81.9 %, 95% CI5 72.4%-
91.4% vs 56.4% and 51.6%-61.2%; P5 .086), but
this effect was not statistically significant.DISCUSSION
Because of the small number of patients, to date
only a few studies have addressed the outcome of chil-
dren with Ph1 CML undergoing BMT with a VUD
[3-5]. The number of patients in the present study is
comparable to that of the largest previous study, which
included 132 children with CML undergoing BMT
from a VUD [4]. Furthermore, unlike that previous
study, our data set contains detailed information on in-
fused total nucleated cell dose, high-resolution HLA
compatibility, and cytogenetic response at the time
of BMT. Until now, these variables have not been
evaluated in a pediatric CML population.
In clinical settings [13-15], as well as in animal
models [16,17], larger cell dose is recognized as an
important predictor of a favorable outcome for alloge-
neic BMT. When an adult patient with CML receives
a transplant from a VUD, a lower infused total nucle-
ated cell dose is associated with an increased incidence
of TRM [18]. Our findings also demonstrate an associ-
ation between lower infused total nucleated cell dose
Biol Blood Marrow Transplant 16:231-238, 2010 237UR-BMT for Children with CMLand lower OS and LFS and a higher incidence of
TRM. These correlations are independent of recipi-
ents’ age. Moreover, all 6 patients who experienced
graft failure were in the lower infused total nucleated
cell dose group. Based on our findings, we recommend
BM harvest teams attempt to collect a higher number
of nucleated cells for infusion in CML patients under-
going BMT from a VUD.
Cytogenetic response to previous treatment with
IFN-a [19] and imatinib [20] has been reported to be
predictive for survival after allogeneic SCT in Ph1
CML. In the multivariate model of our entire cohort,
MCyR at the time of BMT was an independent predic-
tive factor for transplantation outcome. Furthermore,
subgroup analysis of the patients in CP1 confirmed
that the lower TRM rate in patients with MCyR at
the time of BMT contributed to a better survival rate
(Figure 2C), suggesting that MCyR is important for
better transplantation outcome in CP1 CML as well.
Recently, the Center for International Blood and
Bone Marrow Transplant Research reported a signifi-
cantly lower TRM and a better OS in imatinib-treated
patients undergoing allogeneic SCT [21]. In our
cohort, the imatinib-treated patients tended to have
a higher OS (P5 .086), but the difference was not
statistically significant; however, our imatinib-treated
group was small (17 of 125 patients), which may have
reduced the statistical power.
We have now multiple treatment modalities for pe-
diatric CML, including allogeneic SCT, imatinib, and,
more recently, second-generation tyrosine kinase in-
hibitors. Although only few small studies have analyzed
the data on pediatric imatinib monotherapy [22,23],
those studies have reported comparable results to adult
large clinical trials [24-26]. Growth disturbance as a side
effect of imatinib in a pediatric CML patient was re-
ported recently [27]; this effect could be a serious draw-
back to long-term imatinib therapy in the future. Of
course, allogeneic SCT also has potential long-term se-
quelae, including growth retardation. We are currently
planning a study comparing the long-term outcomes
and complications of therapy with tyrosine kinase in-
hibitors and allogeneic SCT in the imatinib era.
In summary, disease phase, infused total nucleated
cell dose, and cytogenetic response at the time of
BMT were found to be independent risk factors for
OS, LFS, and TRM in BMT from a VUD for the treat-
ment of pediatric CML. These results provide impor-
tant information for evaluating indications and
improving outcome in children with CML undergoing
unrelated BMT.ACKNOWLEDGMENTS
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